We used targeted re-sequencing technology in a selected paediatric epilepsy cohort to investigate the impact of genetic testing in diagnosis of CLN2 and other genetic neurodevelopmental disorders featuring early epilepsy. This evidence concerns the gene TPP1 and neurodevelopmental disorder.